CTOs on the Move

PriorAuthNow

www.priorauthnow.com

 
PriorAuthNow`s powerful, secure software works with your EHR system and connects directly with all insurance carriers, making it the fastest, most economical way to submit, monitor and complete prior authorizations.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

PriorAuthNow raised $10.6M on 05/15/2018

Similar Companies

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Anokion

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company`s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion`s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.

Iovance Biotherapeutics

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California.

Polar Electro Inc

Polar Electro Inc is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.